These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28856166)

  • 1. Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
    Bowman C; Abramson V; Wellons M
    J Investig Med High Impact Case Rep; 2017; 5(3):2324709617725351. PubMed ID: 28856166
    [No Abstract]   [Full Text] [Related]  

  • 2. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
    Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
    Liu D; Weintraub MA; Garcia C; Goncalves MD; Sisk AE; Casas A; Harding JJ; Harnicar S; Drilon A; Jhaveri K; Flory JH
    Cancer Med; 2022 Apr; 11(8):1796-1804. PubMed ID: 35212193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
    Novik A V; García B C; Oliva I D
    Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin-associated diabetic ketoacidosis: a case report.
    Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
    Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
    Sahakian N; Cattieuw L; Ramillon-Cury C; Corroller AB; Silvestre-Aillaud P; Béliard S; Valéro R
    Clin Diabetes Endocrinol; 2021 Jul; 7(1):17. PubMed ID: 34281618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition.
    Weintraub MA; Liu D; DeMatteo R; Goncalves MD; Flory J
    Res Sq; 2023 Mar; ():. PubMed ID: 36993733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.
    Vadi S; Agarwal M
    Indian J Crit Care Med; 2017 Nov; 21(11):793-795. PubMed ID: 29279644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
    Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
    Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
    Pujara S; Ioachimescu A
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617710040. PubMed ID: 28589154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Blonde L; Stenlöf K; Fung A; Xie J; Canovatchel W; Meininger G
    Postgrad Med; 2016 May; 128(4):371-80. PubMed ID: 27002421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.
    Hughes CA; Taylor GD
    Ann Pharmacother; 2001; 35(7-8):877-80. PubMed ID: 11485138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrovascular Accident in a High-Risk Patient During the Early Initiation Phase With Canagliflozin.
    Foushee JA; Goodbar NH; Kelly JL; Clarke SL
    Ann Pharmacother; 2014 Aug; 48(8):1066-1069. PubMed ID: 24740468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.